UI Hospitals and Clinics

Clinical Trial Details

Short Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma
Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of Tabalumab in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma

Description

Participants in this research study have been diagnosed with multiple myeloma. Multiple myeloma is a cancer of the plasma cells, found in bone marrow, the blood-producing tissue that fills in spaces within bone. This study is being done to see if the investigational drug (tabalumab) is safe and how well it work to help people with this particular cancer. Researchers also want to investigate how much tabalumab should be given. Does tabalumab with bortezomib and dexamethasone help people with myeloma. Also, to see if the combination of drugs is safe and what side effects are associated with them.

Start Date
November 15, 2012
End Date
November 15, 2022
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Guido Tricot, MD, PhD
Contact Info

Karen Parrott, 319-353-6347

Department
Department or Field of Study
Keywords
bortezomib ; cancer ; dexamethasone ; holstein ; IRB#201205508 ; multiple myeloma ; phase II/III ; phase three ; phase two ; tabalumab ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.